These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 15897532)

  • 1. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
    Kanwal F; Gralnek IM; Martin P; Dulai GS; Farid M; Spiegel BM
    Ann Intern Med; 2005 May; 142(10):821-31. PubMed ID: 15897532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summaries for patients. Antiviral regimens for chronic hepatitis B virus infection.
    Ann Intern Med; 2005 May; 142(10):I39. PubMed ID: 15897528
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.
    Veenstra DL; Sullivan SD; Clarke L; Iloeje UH; Tafesse E; Di Bisceglie A; Kowdley KV; Gish RG
    Pharmacoeconomics; 2007; 25(11):963-77. PubMed ID: 17960954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.
    Kanwal F; Farid M; Martin P; Chen G; Gralnek IM; Dulai GS; Spiegel BM
    Am J Gastroenterol; 2006 Sep; 101(9):2076-89. PubMed ID: 16968510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B.
    Takeda A; Jones J; Shepherd J; Davidson P; Price A
    J Viral Hepat; 2007 Feb; 14(2):75-88. PubMed ID: 17244247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore.
    Lacey LF; Gane E
    J Viral Hepat; 2007 Nov; 14(11):751-66. PubMed ID: 17927611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
    Jones J; Colquitt J; Shepherd J; Harris P; Cooper K
    Health Technol Assess; 2010 May; 14 Suppl 1():23-9. PubMed ID: 20507800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.
    Jones J; Shepherd J; Baxter L; Gospodarevskaya E; Hartwell D; Harris P; Price A
    Health Technol Assess; 2009 Jul; 13(35):1-172, iii. PubMed ID: 19607759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B.
    Buti M; Casado MA; Calleja JL; Salmerón J; Aguilar J; Rueda M; Esteban R
    Aliment Pharmacol Ther; 2006 Feb; 23(3):409-19. PubMed ID: 16423000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
    Wu B; Li T; Chen H; Shen J
    Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.
    Veenstra DL; Sullivan SD; Dusheiko GM; Jacobs M; Aledort JE; Lewis G; Patel KK
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):631-8. PubMed ID: 17625431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of treatments for chronic hepatitis B.
    Wiens A; Lenzi L; Venson R; Pedroso ML; Correr CJ; Pontarolo R
    Braz J Infect Dis; 2013; 17(4):418-26. PubMed ID: 23849851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.
    Wu B; Shen J; Cheng H
    BMC Health Serv Res; 2012 Nov; 12():385. PubMed ID: 23137013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea].
    Kim BK; Kwon SY; Lee CH; Choe WH; Choi HM; Koo HW
    Korean J Hepatol; 2009 Mar; 15(1):25-41. PubMed ID: 19346783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An economic evaluation of different treatments for HBeAg-positive chronic hepatitis B in China].
    Larry L; Lu XZ; Alison T
    Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):431-6. PubMed ID: 17594808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
    Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
    Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
    Saab S; Ham MY; Stone MA; Holt C; Tong M
    Liver Transpl; 2009 Apr; 15(4):413-20. PubMed ID: 19326401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
    Yuan Y; Iloeje UH; Hay J; Saab S
    J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.